billHR7505Event Wednesday, February 11, 2026Analyzed

Flexible Leave Act

Neutral

Summary

HR 7505 (Flexible Leave Act) is an early-stage bill referred to committee with no hearing schedule, no funding mechanism, and no direct market impact at this stage. Stock movements for mentioned companies are uncorrelated with this bill's activity.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR7505 is an early-stage bill with no hearings, no funding, and no market impact
  • 2.The bill is procedural — it modifies FMLA leave scheduling rules, not spending or regulation
  • 3.No tickers are actionable; stock movements for mentioned companies are unrelated to this bill

Market Implications

No market implications. The bill has not advanced beyond committee referral with no scheduled hearings. Retail investors should not trade based on this legislation at this stage.

Full Analysis

The Flexible Leave Act (HR7505), introduced on February 11, 2026, by Rep. McBride (D-DE), proposes to amend the Family and Medical Leave Act of 1993 to allow all leave to be taken on an intermittent schedule. The bill is in the earliest legislative stage: referred to three committees (Education and Workforce, Oversight and Government Reform, House Administration) with no hearing scheduled and no further action in over two months. The bill authorizes no funding, creates no tax incentives, and imposes no mandates on private companies beyond existing FMLA compliance. The only affected entities would be FMLA-covered employers (those with 50+ employees) if the bill becomes law, but the change is administrative — removing certification requirements for intermittent leave — rather than creating new costs or revenue streams. At this procedural stage, there is no identifiable market impact for any publicly traded company. No causal chain can be constructed from this bill's text to any specific company's revenue, costs, or competitive position.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.